The Italian Group has announced a new commercial agreement with the multinational company Novartis for high-level products

Fidia has recently announced a new commercial partnership with the Italian subsidiary of Novartis…
Fidia's wholly owned subsidiary, Fidia Pharma USA Inc., introduces in the US, TRILURON™ , a…

The Italian company has announced two major investments in Spain with the acquisition of three ophthalmic products on the Spanish market from the multinational company Novartis, and the acquisition of the Spanish company Soluciones Bioregenerativas SL.

Fidia, an Italian multinational pharmaceutical company, has announced the acquisition of three…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine